Status:
COMPLETED
NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Neurofibromatosis Type 1
Eligibility:
All Genders
7-12 years
Phase:
PHASE4
Brief Summary
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with an estimated prevalence of 1/2190 to 1/6711. Attention deficit hyperactivity disorder (ADHD) has been reported to be common in NF1...
Eligibility Criteria
Inclusion
- Age 7-12 years
- IQ between 80-120.
- Gender: male or female
- Children with neurofibromatosis type 1 (according to the National Institutes of Health \[NIH\] 1988).
- Patients with school difficulties pointed out by parents or teachers
- Patients with attention difficulties as defined by anamnesis
Exclusion
- IQ \> 120 or IQ \< 80
- Child depression
- Unwillingness to participate
- Patients with cerebral complication of neurofibromatosis type 1 (chiasma glioma, moya-moya) as detected by cerebral magnetic resonance imaging (MRI).
- Participation in another study
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2011
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00169611
Start Date
January 1 2004
End Date
January 1 2011
Last Update
January 27 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Laurence LION-FRANCOIS
Lyon, France, 69005